Tokyo, Japan (October 5, 2015)
Swiss Medendi’s patent has been granted by the Japan Patent Office. The patent covers the core technology of Swiss Medendi’s novel infusion device. The innovation was confirmed to fulfill all three patent criteria: Innovative, inventive, and commercially applicable. The patent strengthens the protection of Swiss Medendi’s intellectual property in Japan and will be valid until 2035.
About Swiss Medendi
Swiss Medendi SA is a Switzerland based start-up company offering a proprietary, cost-efficient and easy-to-use intravenous (IV) infusion device, the HC100, for safe administration of chemotherapeutics and other vesicant and irritant drugs – protecting patients’ veins and vessels from vesicant damages, and preventing patients from injuries and complications associated today with ports and catheters. Employing the HC100 will help hospitals to manage costs and enable doctors to focus more on their patients’ needs.